Mayo Clinic Researchers Enhanced Thyroid Cancer Treatment

A new strategy uses MAPK inhibitors to restore antigens and improve CAR-T cell performance against thyroid tumors.

Updated on Sept. 21, 2026 in Cancer

High-end medical microscope and glass research slides on a stainless steel laboratory workbench in a clinical setting. — Mayo Clinic researchers have discovered a strategy using MAPK inhibitors to improve the effectiveness of CAR-T cell therapy against aggressive thyroid tumors. AI Illustration. Upload story photo >

Live Poll

Should cancer research prioritize altering tumor biology over engineering immune cells to improve treatment success?

Mayo Clinic researchers have identified a method to restore thyroid-stimulating hormone receptor (TSHR) expression on cancer cells. This breakthrough allows CAR-T cells to better identify and destroy aggressive thyroid tumors.

Why it matters

Solid tumors often shed antigens, allowing them to hide from immune therapies like CAR-T cells. This new strategy may overcome those defenses to treat metastatic disease that is currently difficult to manage.

Approximately 2,500 Americans die annually from metastatic thyroid cancer. Researchers found that two weeks of concurrent treatment with MAPK inhibitors improved tumor control in preclinical models.

The players

Mayo Clinic

This is a non-profit American academic medical center focused on integrated health care, education, and research.

The details

Researchers used MAPK pathway inhibitors, such as trametinib and dabrafenib, to force thyroid cancer cells to redifferentiate. This process restores TSHR expression, enabling CAR-T cells to multiply and activity levels to remain high without interference from the drugs.

September 21, 2026: The research findings were published.

Cancer
Sept. 22
Blinatumomab Improved Survival in Pediatric Leukemia
Cancer
Sept. 22
Researchers Identified B Cells as Colitis Drivers
Cancer
Sept. 22
U.S. Cancer Death Rates Have Continued to Decline

The Big Picture

This study updates the trajectory of the TSHR-targeted CAR-T cells research program by providing a mechanism to sustain antigen expression. It marks a departure from previous models that struggled with tumor antigen loss.

This research provides a potential pathway for more effective immunotherapy options for patients with metastatic thyroid cancer. Clinical trials are currently being organized to test these findings in human patients.

The takeaway

This study demonstrates how combining traditional targeted inhibitors with advanced cell therapy can outmaneuver tumor evasion tactics. Such dual-action approaches represent a growing trend in overcoming the limitations of current oncology treatments.